

List of Figures

Chapter 2

Figure 2.1 First Pass (Pre-systemic) Metabolism	12
Figure 2.2 Digestion and absorption pathway of Dietary Lipid	13
Figure 2.3 Pseudo ternary phase diagram showing zones of emulsion	19
Figure 2.4 Niosomes structure showing bilayer formed by surfactant molecules	25
Figure 2.5 Chemical structure of Iloperidone	34
Figure 2.6 ILO's antagonistic action on receptors	35
Figure 2.7 Chemical structure of Vardenafil HCl trihydrate	41
Figure 2.8 Mechanism of action of VDN	43

Chapter 3

Figure 3.1 Schematic of SANS instrument.....	63
--	----

Chapter 4

Figure 4.1 Calibration curve of ILO in pH 6.8 phosphate buffer	70
Figure 4.2 Calibration curve of ILO in methanol	72
Figure 4.3 Calibration curve for ILO by HPLC.....	74
Figure 4.4 Chromatogram of ILO by HPLC.....	75
Figure 4.5 MRM transition of ILO for Mass detection	77
Figure 4.6 Calibration curve of ILO by UPLC-MS	78
Figure 4.7 Retention time of ILO in UPLC-MS	78
Figure 4.8 Calibration curve of VDN in pH 6.8 phosphate buffer	80
Figure 4.9 Calibration curve of VDN in acetonitrile	82
Figure 4.10 Calibration curve for VDN by HPLC.....	84
Figure 4.11 Chromatogram of VDN by HPLC.....	84
Figure 4.12 MRM transition of VDN for Mass detection	87
Figure 4.13 Calibration curve of VDN by UPLC-MS	87
Figure 4.14 Retention time of VDN in UPLC-MS.....	88

Figure 4.18 Chromatogram for standard solution of methanol – chloroform.....	90
--	----

Chapter 5

Figure 5.1 MLP feedforward back propagation network.....	97
--	----

Figure 5.2 Niosomes bilayer structure	104
---	-----

Chapter 6

ILO SMEDDS

Figure 6.1 Solubility Study of ILO for SMEDDS development	118
---	-----

Figure 6.2 Micro-Emulsification efficiency of non-ionic surfactants	120
---	-----

Figure 6.3 Pseudo-ternary phase diagram for ILO SMEDDS for oil (1:2 Capmul MCM C8: Oleic Acid) + Smix (Cremophor EL + Transcutol HP) titrated against water	122
---	-----

Figure 6.4 Fraction of Design Space (FDS) graph	124
---	-----

Figure 6.5 Predicted Graph for Response - Size (nm)	125
---	-----

Figure 6.6 2D contour plot for droplet size.....	126
--	-----

Figure 6.7 Globule size of optimized formulation.....	127
---	-----

Figure 6.8 Architecture of Artificial neural network for optimization of globule size.....	128
--	-----

Figure 6.9 Regression of dataset using MATLAB for measuring size of globules of ILO SMEDDS	129
--	-----

Figure 6.10 Effect of input variables on output	130
---	-----

Figure 6.11 Relative contribution of each ingredient on size	131
--	-----

Figure 6.12 Scattered intensity as observed by SANS for ILO SMEDDS	132
--	-----

Figure 6.13 Zeta potential of diluted ILO SMEDDS.....	134
---	-----

Figure 6.14 Cryo-TEM of ILO SMEDDS	135
--	-----

Figure 6.15 Rheology study of ILO SMEDDS.....	136
---	-----

Figure 6.16 In vitro drug release study	138
---	-----

Figure 6.17 Ex vivo drug release study of ILO SMEDDS	139
--	-----

VDN SMEDDS

Figure 6.18 Solubility study of VDN.....	141
--	-----

Figure 6.19 Emulsification efficiency of non-ionic surfactant	142
Figure 6.20 Pseudo-ternary phase diagram for VDN SMEDDS using Cremophor EL	145
Figure 6.21 Pseudo-ternary diagram for VDN SMEDDS using Tween 20 Oil (Capmul MCM C8) + Smix (Tween 20 + PEG 200) titrated against water	146
Figure 6.22 Predicted vs Actual plot for Globule size (Y1)	149
Figure 6.23 Effect of independent factors on globule size	151
Figure 6.24 Predicted vs Actual plot for % transmittance (Y2)	152
Figure 6.25 Effect of independent variables on %transmittance of VDN SMEDDS	154
Figure 6.26 Desirability plot for VDN SMEDDS	155
Figure 6.27 Overlay plot showing knowledge space for VDN SMEDDS	157
Figure 6.28 Design space for VDN SMEDDS	157
Figure 6.29 Control space for VDN SMEDDS	158
Figure 6.30 O/W microemulsion droplet defining size parameters by DLS (D_h) and SANS (D_{core})	160
Figure 6.31 Scattered intensity as observed by SANS for VDN SMEDDS	161
Figure 6.32 Cryo-TEM of VDN SMEDDS	163
Figure 6.33 Rheology Study of VDN SMEDDS	164
Figure 6.34 In vitro drug release study of VDN SMEDDS	165
Figure 6.35 Ex vivo drug release study of VDN SMEDDS	167

ILO Niosomes

Figure 6.36 Fishbone diagram for selection of factors for niosomes development.....	173
Figure 6.37 GC chromatograph at the end of 30 min of solvent evaporation time	176
Figure 6.38 Predicted vs Actual plot for %EE.....	182
Figure 6.39 Contour plot showing effect of independent variables on %EE.....	185
Figure 6.40 Predicted vs Actual plot for size.....	186
Figure 6.41 Contour plot showing effect of independent variables on Size	189
Figure 6.42 Desirability plot for ILO Niosomes.....	190
Figure 6.43 Control space for ILO Niosomes.....	192

VDN Niosomes

Figure 6.44 Effect of Span 60 and cholesterol on %EE	194
Figure 6.45 Effect of Span 60 and cholesterol on Size.....	195
Figure 6.46 Effect of drug on %EE	196
Figure 6.47 Effect of drug on Size.....	196
Figure 6.48 2D contour plot showing effect of independent variables on %EE.....	197
Figure 6.49 3D plot showing complex interaction of independent variables for %EE	198
Figure 6.50 2D contour plot showing effect of independent variables on size.....	199
Figure 6.51 3D plot showing complex interaction of independent variables for size	199
Figure 6.52 Desirability plot for VDN Niosomes.....	201
Figure 6.53 Overlay plot showing control space for VDN Niosomes.....	202
Figure 6.54 Bilayer thickness measurement of ILO niosomes using SANS	204
Figure 6.55 Bilayer thickness measurement of VDN niosomes using SANS	205

Niosomes - characterization

Figure 6.56 Bilayer thickness of blank niosomes prepared as per ILO Niosomes optimized formula	205
Figure 6.57 Bilayer thickness of blank niosomes prepared as per VDN Niosomes optimized formula.....	206
Figure 6.58 Cryo-TEM images of A) ILO niosomes and B) VDN niosomes	207
Figure 6.59 DSC study for niosomes.....	208
Figure 6.60 FTIR Spectra for Drug-Excipient Compatibility.....	210
Figure 6.61 In vitro drug release of ILO and VDN Niosomes	211
Figure 6.62 Ex vivo drug release of niosomes.....	211

Chapter 7

Figure 7.1 MTT dye reduction by mitochondrial reductase enzyme.....	220
Figure 7.2 Caco-2 cell viability after 4 h incubation with drug and formulations of ILO.....	221
Figure 7.3 Caco-2 cell viability after 4 h incubation with drug and formulations of VDN...	221
Figure 7.4 Study of cellular uptake of formulations in Caco-2 cell line after 4 h incubation	223

Figure 7.5 Comparative Dot plot analysis of uptake of coumarin 6 loaded formulations in Caco2 cell line (A: Control, B: ILO Niosomes, C: VDN Niosomes, D: ILO SMEDDS, E: C-EL VDN SMEDDS, F: T-20 VDN SMEDDS)	225
Figure 7.6 % Fluorescence intensity after treatment with formulation in Caco2 cells	226
Figure 7.7 Apparent Permeability co-efficient (Papp) for Apical to Basolateral direction for the tested compounds	228
Figure 7.8 Actin visualization (A-control, B-ILO Niosomes, C-VDN Niosomes, D-ILO SMEDDS, E- C-EL VDN SMEDDS, F- T-20 VDN SMEDDS)	231
 Chapter 8	
Figure 8.1 Griess reaction to detect nitrite level	241
Figure 8.2 Concentration of ILO in plasma after oral administration of formulations	245
Figure 8.3 Concentration of VDN in plasma after oral administration of formulations	247
Figure 8. 4 Effect of ILO and its formulations on fall off time in Rota-rod test in MK 801 induced psychosis in mice	251
Figure 8.5 Effect of ILO and its formulations on immobility time in forced swim test in MK 801 induced psychosis in mice	252
Figure 8.6 Effect of ILO and its formulations on Brain Nitrite level in MK 801 induced psychosis in mice	254
Figure 8.7: Sperm count study for VDN and its formulations	259
Figure 8.8: Hematoxylin – Eosin staining of Penis	260
Figure 8.9: Masson Trichome Staining of Penis A-Normal Control, B- Disease Control, C-Drug Suspension, D-SMEDDS Formulation, E-Niosomes Formulation	261
Figure 8.10 Hematoxylin – Eosin staining of Testis	262
Figure 8.11 Masson Trichome Staining of Testis A-Normal Control, B- Disease Control, C-Drug Suspension, D-SMEDDS Formulation, E-Niosomes Formulation	264